MP09-10 PROSTATE IMAGING-REPORTING AND DATA SYSTEM VERSION 2 IN COMBINATION WITH CLINICAL PARAMETERS FOR PROSTATE CANCER DETECTION

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP09-10 PROSTATE IMAGING-REPORTING AND DATA SYSTEM VERSION 2 IN COMBINATION WITH CLINICAL PARAMETERS FOR PROSTATE CANCER DETECTION Lei Wang, Yi Luo, Tongzu Liu, Ming Deng, Hiroaki Wakimoto, and Xing Huang Lei WangLei Wang More articles by this author , Yi LuoYi Luo More articles by this author , Tongzu LiuTongzu Liu More articles by this author , Ming DengMing Deng More articles by this author , Hiroaki WakimotoHiroaki Wakimoto More articles by this author , and Xing HuangXing Huang More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003224.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The purpose of this study was to analyze the diagnostic performance of the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) in combination with clinical parameters in patients with suspected prostate cancer (PCa). METHODS: A total of 424 men with suspicion of PCa were retrospectively analyzed, who underwent multiparametric magnetic resonance imaging (mpMRI) evaluated with PI-RADS v2 prior to transperineal ultrasound guided systematic biopsy. Clinical parameters including age, prostate volume, prostate specific antigen (PSA), free/total PSA ratio (f/t PSA), PSA density (PSAD) and PI-RADS v2 score were investigated. Logistic regression analyses were performed to identify predictors of clinically significant PCa defined as a Gleason score of 3 + 4 or greater. The prediction performance was compared with PSA level, f/t PSA, PSAD, PI-RADS v2 alone, and PI-RADS v2 plus PSAD using receiver operating characteristics (ROCs). RESULTS: In total, 231 out of 424 cases (54.48%) were pathologically diagnosed as PCa. The percentage of clinically significant PCa was higher in patients with PI-RADS v2 score of 4 or greater compared to PI-RADS v2 score of less than 4 (90.86% vs. 55.88%, p < 0.001). Age, PSA level, f/t PSA, PSAD, and PI-RADS v2 were significant independent predictors of clinically significant PCa (Figure 1). The ROC area under the curve of PI-RADS v2 plus PSAD (0.952) was larger compared with PSA (0.845), f/t PSA (0.719), PSAD (0.920), and PI-RADS v2 alone (0.885) (Table 1, Figure 2). CONCLUSIONS: PI-RADS v2 in combination with PSAD may help detect clinically significant PCa and provide benefit in making the decision to biopsy men at suspicion of PCa. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e108 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Lei Wang More articles by this author Yi Luo More articles by this author Tongzu Liu More articles by this author Ming Deng More articles by this author Hiroaki Wakimoto More articles by this author Xing Huang More articles by this author Expand All Advertisement PDF downloadLoading ...